|
NxStage® Announces Streamline® Blood
Tubing Set Supply Agreement Between Medisystems® and Reliant
Renal Care
LAWRENCE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of
innovative dialysis products, today announced that its
wholly-owned subsidiary, Medisystems Corporation, has signed a
new three-year product supply agreement with Reliant Renal Care,
Inc., for the delivery of Streamline airless blood tubing sets,
as well as MasterGuard® safety needles with FingerShield® to
Reliant's dialysis center network.
"With nearly two million treatments to date, our Streamline
blood tubing set continues to gain traction in the market. As
such, we are very pleased that Reliant has selected both
Streamline and our MasterGuard needles for integration into
their in-center operations," stated Mark S. Florence, Vice
President and General Manager of Medisystems Corporation. "This
combination of innovative and proven technologies underscores
our commitment to bring added clinical and economical value to
our customers for the benefit of dialysis patients."
"Reliant is committed to ensuring that our providers have access
to innovative and effective health care technology," stated Nola
McMullen, Executive Vice President and COO of Reliant Renal
Care, Inc. "It is RRC's philosophy that improvements in patient
care happen at the chair side; Streamline's ability to reduce
alarm occurrences, improve our clearances, and reduce our costs,
and the unique safety features of MasterGuard, make the
Medisystems' products a good match with our efforts to offer
extended modality choices (in-center self care, home
hemodialysis and in-center nocturnal programs) to each patient,
all the while maintaining safety requirements for patients and
caregivers."
Medisystems' latest generation blood tubing set is the
Streamline. Streamline features an efficient and airless design
intended to improve clinical and economic performance.
Streamline is designed to reduce dialysate flow, dialyzer size,
treatment time, minimize heparin and waste, and optimize dose
delivery, as measured in Kt/V. Streamline also includes
Medisystems' patented LockSite® ( )needleless access ports,
which eliminate the need for sharp needles or costlier guarded
needles to be used with the tubing set during dialysis.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device
company, headquartered in Lawrence, Massachusetts, USA, that
develops, manufactures and markets innovative products for the
treatment of ESRD and acute kidney failure. For more information
on NxStage and its products, please visit the company's website
at http://www.nxstage.com. For more information on Medisystems
products, please visit
http://www.medisystems.com.
About Reliant Renal Care
Based in Media Pennsylvania, Reliant Renal Care, Inc. provides
dialysis services to patients with chronic kidney failure, also
known as end-stage renal disease (ESRD). Reliant is the only
investor-owned dialysis center company led by clinicians.
Reliant works to continually improve each center's performance
through innovation and cost control. The company acquires,
develops, and manages dialysis centers in partnership with
physicians.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors including, but not limited
to, changes relating to customer demand for NxStage's Streamline
blood tubing sets, MasterGuard needles and other products and
other factors that are discussed in NxStage's filings with the
Securities and Exchange Commission, including the Quarterly
Report on Form 10-Q for the quarter ended June 30, 2009. NxStage
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact
Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard @nxstage.com
Source
NxStage Medical, Inc.
|
